Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2023 | Current trials of interest in CLL

Barbara Eichhorst • 7 Oct 2023
iwCLL 2023
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Antibodies BTK inhibitors Obinutuzumab Pirtobrutinib Venetoclax
MAJIC

In this interview, Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, highlights trials of interest in the field of chronic lymphocytic leukemia (CLL) treatment – the Phase III CLL18 trial beginning at the end of 2024 and the MAJIC trial (NCT05057494). This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Barbara Eichhorst

1:05
Risk-factors for Richter’s transformation
Barbara Eichhorst • 10 Dec 2023
2:01
Updated follow-up results of the Phase III GAIA/CLL13 trial
Barbara Eichhorst • 10 Dec 2023
2:08
CLL-RT1 trial: primary endpoint analysis of tislelizumab plus zanubrutinib in patients with RT
Barbara Eichhorst • 10 Dec 2023
0:45
Cys-ser mutation-driven ibrutinib resistance and alternative BTKi’s under development
Barbara Eichhorst • 7 Oct 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals